Dose‐finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors. Issue 10 (4th October 2018)

• Record Type: Journal Article
• Authors: Iwasa, Satoru; Yamamoto, Noboru; Shitara, Kohei; Tamura, Kenji; Matsubara, Nobuaki; Tajimi, Masaomi; Lin, Aimee B.; Asou, Hiroya; Cai, Zhihong; Inoue, Koichi; Shibasaki, Yuko; Saito, Kanako; Takai, Hiroki; Doi, Toshihiko
• Is Part Of: Cancer science. Volume 109:Issue 10(2018)
• Page Start: 3216
• Page End: 3223
• Publication Date: 2018-10-04
• Subjects: Checkpoint kinase 1 -- Japan -- phase I clinical trial -- prexasertib -- solid tumors; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.13750
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract : Prexasertib is a novel inhibitor of checkpoint kinase 1. The primary objective of this study was to evaluate prexasertib tolerability in Japanese patients with advanced solid tumors. This nonrandomized single‐arm open‐label phase 1 study of prexasertib consisted of 2 dose levels, 80 mg/m 2 and the global‐recommended dose based on a US study of 105 mg/m 2, administered intravenously once every 14 days (n = 6 for each dose). Transition to the higher dose proceeded if the frequency of dose‐limiting toxicity observed in cycle 1 was <33% at the lower dose. Safety measures, pharmacokinetics and antitumor activity were assessed. A total of 12 patients were treated. Two patients, one in each dose group, experienced dose‐limiting toxicities of febrile neutropenia, one grade 4 and the other grade 3; both patients recovered and continued the study treatment. The grade 4 treatment‐emergent adverse events related to study treatment were neutropenia (6 patients [50.0%]), leukopenia (4 patients [33.3%]), and 1 instance each (8.3%) of anemia, febrile neutropenia and thrombocytopenia. Neutropenia was generally transient and reversible; 11 patients (91.7%) required granulocyte colony‐stimulating factor treatment during the study. There were no discontinuations due to adverse events or deaths. The prexasertib pharmacokinetics displayed dose‐independent and time‐independent behavior across both dose levels, similar to the profile observed in the US‐based phase 1 study. Eight patients had a best overall response of stable disease. These data are consistent with the known safety profile for prexasertib and confirm its tolerability in Japanese patients with advanced solid tumors. Abstract : Prexasertib is a novel inhibitor of checkpoint kinase 1. In this nonrandomized single‐arm open‐label phase 1 study, we confirmed its tolerability in Japanese patients with advanced solid tumors.